Known targets — ChEMBL curated mechanism
AGTR1DHFRGABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTNR3C2PBP2XPTGS1PTGS2VKORC1blablaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAftsImrcAmrcBmrdApbp1apbp1bpbp2apbp2bpbp3polthyA
The experimentally established mechanism targets of Potassium Ion. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 6/20 | 0.36 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.33 |
| ▸ | HIPK2 | Q9H2X6 | 1/20 | 0.33 |
| ▸ | CRACR2A | Q9BSW2 | 2/20 | 0.33 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.32 |
| ▸ | CYP46A1 | Q9Y6A2 | 1/20 | 0.32 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.31 |
| ▸ | JAK2 | O60674 | 1/20 | 0.31 |
| ▸ | JAK1 | P23458 | 1/20 | 0.31 |
| ▸ | TYK2 | P29597 | 1/20 | 0.31 |
| ▸ | JAK3 | P52333 | 1/20 | 0.31 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.31 |
| ▸ | CDC7 | O00311 | 1/20 | 0.31 |
| ▸ | PIM1 | P11309 | 1/20 | 0.31 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.31 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.31 |
| ▸ | SPR | P35270 | 1/20 | 0.31 |
| ▸ | PRKG1 | Q13976 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1290058 | 0.90 | KDM4C (0.39) | CYP17A1MAPK13CRACR2AKDM4CCYP46A1 | |
| SCHEMBL12502392 | 0.88 | ROCK2 (0.36) | CYP17A1MAPK13CRACR2AKDM4CROCK2 | |
| Potassium Ion SCHEMBL1290169 | 0.85 | CYP46A1 (0.35) | HIPK2CYP46A1 | |
| Potassium Ion SCHEMBL1290292 | 0.83 | FBP1 (0.30) | MAPK13 | |
| Potassium Ion SCHEMBL1290125 | 0.82 | CYP1A2 (0.40) | — | |
| SCHEMBL15261609 | 0.81 | KDM4C (0.38) | CYP17A1KDM4CCYP46A1JAK2JAK1 | |
| Potassium Ion SCHEMBL12502015 | 0.80 | HSD17B1 (0.32) | MAPK13 | |
| Potassium Ion SCHEMBL1290133 | 0.79 | MAPK13 (0.31) | MAPK13 | |
| Potassium Ion SCHEMBL12502530 | 0.79 | KDM4E (0.31) | — | |
| Potassium Ion SCHEMBL12502176 | 0.79 | CCNC (0.34) | JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3476844-A1 | ANTIMICROBIAL 4-OXOQUINOLIZINES | Emergent Product Development Gaithersburg Inc. (US) | 2019-05-01 | — | — | EP | disclosed |
| US-20190105367-A1 | ANTIMICROBIAL 4-OXOQUINOLIZINES | EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC. (US) | 2019-04-11 | — | — | US | disclosed |
| US-10155021-B2 | Antimicrobial 4-oxoquinolizines | EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC. (US) | 2018-12-18 | — | — | US | disclosed |
| EP-3312176-A1 | ANTIMICROBIAL 4-OXOQUINOLIZINES | Emergent Product Development Gaithersburg Inc. (US) | 2018-04-25 | — | — | EP | disclosed |
| US-20170232060-A9 | ANTIMICROBIAL 4-OXOQUINOLIZINES | EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC. | 2017-08-17 | — | — | US | disclosed |
| US-20170106045-A1 | ANTIMICROBIAL 4-OXOQUINOLIZINES | EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC. | 2017-04-20 | — | — | US | disclosed |
| US-9403818-B2 | Antimicrobial 4-oxoquinolizines | EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC. (US) | 2016-08-02 | — | — | US | disclosed |
| EP-2670410-A1 | ANTIMICROBIAL 4-OXOQUINOLIZINES | Evolva SA (CH) | 2013-12-11 | — | — | EP | disclosed |
| US-20130252882-A1 | ANTIMICROBIAL 4-OXOQUINOLIZINES | EVOLVA SA (CH) | 2013-09-26 | — | — | US | disclosed |
| WO-2012104305-A1 | ANTIMICROBIAL 4-OXOQUINOLIZINES | EVOLVA SA (CH) | 2012-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190105367-A1 | ANTIMICROBIAL 4-OXOQUINOLIZINES | CUL4A, DCAF15, CUL4B | CYP17A1 2248/4885MAPK13 3233/4885HIPK2 3948/4885 |
| US-10155021-B2 | Antimicrobial 4-oxoquinolizines | DCAF15, CUL4A, CUL4B | CYP17A1 2377/4885MAPK13 3168/4885HIPK2 3896/4885 |
| US-20170106045-A1 | ANTIMICROBIAL 4-OXOQUINOLIZINES | CUL4A, DCAF15, CUL4B | CYP17A1 2248/4885MAPK13 3233/4885HIPK2 3948/4885 |
| US-20170232060-A9 | ANTIMICROBIAL 4-OXOQUINOLIZINES | CUL4A, DCAF15, CUL4B | CYP17A1 2248/4885MAPK13 3233/4885HIPK2 3948/4885 |
| US-20130252882-A1 | ANTIMICROBIAL 4-OXOQUINOLIZINES | CUL4A, DCAF15, CUL4B | CYP17A1 2248/4885MAPK13 3233/4885HIPK2 3948/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.